Genetic profiles of plasmacytoid (BDCA-4 expressing) DC subtypes-clues to DC subtype function in vivo
© Wrzesinski et al.; licensee BioMed Central Ltd. 2013
Received: 21 November 2012
Accepted: 5 March 2013
Published: 9 March 2013
Among the dendritic cell (DC) subsets, plasmacytoid DC’s (pDC) are thought to be important in the generation of both antiviral and antitumor responses. While pDC may be useful in developing dendritic cell-based tumor vaccines, the low frequency of these cells in the peripheral blood has hampered attempts to understand their biology. To provide better insight into the biology of pDC, we isolated these unperturbed cells from the peripheral blood of healthy donors in order to further characterize their gene expression. Using gene array technology we compared the genetic profiles of these cells to those of CD14+ monocytes isolated from the same donors and found several immune related genes upregulated in this cell population. This is the first description, to our knowledge, of gene expression in this subset of DCs obtained from the peripheral blood of adult human donors without exposure in vitro to cytokine or growth factors. Understanding the natural genetic profiles of this dendritic cell subtype as well as others such as the BDCA-1 expressing myeloid DCs may enable us to manipulate these cells ex-vivo to generate enhanced DC-based tumor vaccines inducing more robust antitumor responses.
KeywordsPlasmacytoid dendritic cells Gene expression Granzyme B
Dendritic cells are paramount in generating cell-mediated and humoral immune responses and have been utilized for cancer vaccines against melanoma, prostate cancer, renal cell carcinoma, and non-Hodgkin’s lymphoma with varying results, including an FDA approved therapy for prostate cancer patients [1–5]. The DC’s used in many of these trials are generated from a heterogenous group of immature peripheral blood DC’s and CD14+ cells obtained from cancer patients. These cells are expanded ex vivo in the presence of GM-CSF and Interleukin-4, subjected to antigen loading, maturation and subsequently reintroduced into the donor. The heterogeneity of the DCs confounds the overall results observed in the patients’ antitumor responses in these trials.
Although there can be plasticity of function between DC subtypes , in general, myeloid DCs (mDC) and plasmacytoid DCs (pDC) are considered to induce cell-mediated (TH1 type) and humoral (TH2) responses respectively. Blood DC antigen (BDCA) 1 and 4 are preferentially expressed on mDC and pDC respectively and can be exploited to isolate pure populations of these cell types . While mDC have been characterized both in healthy donors and cancer patients , the low frequency of pDC in the peripheral blood compartment has prevented extensive evaluations of this cell population. Little is known about the de novo state of pDC. Until recently , peripheral blood pDC have not been well-characterized and the biology of these cells has been established using either murine or human cells expanded in culture from CD34+ precursors . Because of their ability to produce high levels of type I (α and β) interferons, pDC are thought to play a role in augmenting antiviral responses . More recently these cells have also been demonstrated to synergize with mDCs to induce antigen-specific antitumor responses against ova-expressing murine thymomas  and basal cell cancers . These studies suggest that initiating DC expansion from pure DC precursors (pDCs or mDCs) would be an attractive strategy for human DC vaccine development. Understanding the biology of de novo DC subsets could help to determine the optimal use of these cells in tumor vaccine studies. Therefore, we isolated and evaluated the gene expression profiles of human pDCs.
Materials and methods
pDC isolation and purification by MACS and FACS
After signing consent per Protocol D9726 (Committee for the Protection of Human Subjects#12756), healthy adult donors were tested for viral serologies (HIV, Hepatitis) and underwent leukapheresis using a Cobe Spectra Apheresis System (Lakewood, CO) if viral titers were negative. Each leukopak was then subjected to Ficol-gradient isolation and resulting peripheral blood mononuclear cells (PBMC) were stored in RPMI containing autologous serum overnight at 4°C.
The following day 1.1 x 109 donor PBMC were stained with defined iron-conjugated antibodies and magnetically sorted as per Miltenyi Biotec protocol on the autoMACS. (Miltneyi Biotec, Auburn CA). The labeled cells were subjected to FACS using a FACStar Plus cytometer by pre-gating on the subset of CD3- and CD20- cells, and then gating on the BDCA-4 positive cells in this subset. Cell populations with at least 95% purity by FACS analysis were used for subsequent experiments.
Gene array evaluation of BDCA-4 cells and confirmation of upregulated genes by RT-PCR
RNA was extracted using the Quiagen RNeasy method (Quiagen, Valencia, CA). The RNA was subsequently labeled and hybridized to the HU133A gene chip using the method established by Affymetrix and run on the Affymetrix system (Affymetrix, Santa Clara, CA). The gene expression data was subjected to analysis by the Iobion Gene Traffic ® software as described below.
TLR7 forward AAT GTC ACA GCC GTC CCT AC
TLR7 reverse TTA TTT TTA CAC GGC GCA CA
GZMB forward ATG CAA CCA ATC CTG CTT CT
GZMB reverse TTA TGG AGC TTC CCC AAC AG
Cmklr1 forward CGT CTT CCT CCC AAT CCA TA
Cmklr1 reverse AAG AAA GCC AGG ACC CAG AT
My iQ Single Color Real-Time PCR Detection system was used to perform real-time RT-PCR (Bio-Rad, Hercules, CA). Amplification of β-actin was used as an endogenous reference gene.
CellQuest software was used to analyze the purity of the BDCA-4 cells obtained by MACS and FACS.
Differential gene expression was evaluated by Iobion Gene Traffic ® software by using differential gene expression of greater than or less then 3 fold between groups  as described below. CD14 monocytes obtained from the same donor served as the baseline gene array profile for all analyses (see Gene Expression Omnibus [GEO] GSE11943 for full sets of gene array data).
Affymetrix image and data files were directly imported in GeneTraffic Uno Microarray Data Management and Analysis Software Version 3.2, Iobion Informatics LLC, La Jolla, CA. Data was normalized by transforming with Robust Multichip Analysis (RMA) . Fold change values were generated by comparing BDCA-4 chips to CD14 chips from the same donor. The dataset was filtered to remove genes without at least one instance of expression change that was greater than or less than an absolute fold change value of 3 across 4 separate gene arrays (one array per four separate BDCA-4 cell isolations). The resulting genes were analyzed using Significance Analysis of Microarrays (SAM)  to determine reproducibility across replicates as well as identify significant expression changes between cell types. Using a two-class paired test with a significance cutoff of 0.001%, 1232 genes were identified that were significantly up or down-regulated when compared to CD14 cells. Subsets of differentially expressed genes were further analyzed using Onto-Express  to identify significantly represented ontology groups.
Gene arrays to evaluate the gene expression in DC’s during maturation in vitro have revealed upregulation of genes involved in cell adhesion and motility, immune response, growth control and lipid metabolism affecting cell growth and differentiation, signal transduction, ion channel activities and membrane function [18–20]. More recently Lindstedt et al. published the gene family clustering of human blood and tonsillar DC subsets from healthy children undergoing tonsillectomy using Affymetrix gene arrays . We chose the Affymetrix system to assess gene profiles of pure populations of unstimulated de novo BDCA-4 cells obtained from consented healthy adult donors.
Our data demonstrate unique immune-related genes expressed in adult peripheral blood plasmacytoid dendritic cell subtypes relative to autologous CD14 monocytes and complement the previously reported differential gene expression of DC subsets obtained from the peripheral blood and tonsils of children .
Interestingly, we found a slightly different pDC gene expression profile compared to that reported by Lindstedt et al. While our results also demonstrate several immune-related genes upregulated in this subset including IL18R1, IL3RA (CD123) and TLR-7, additional upregulated genes not reported by Lindstedt et al. included the leukocyte-associated immunoglobulin like receptor, IL-18 receptor accessory protein, and lymphotoxin beta. One limitation of our study was that with the human HU133A chip we could not assess the previously demonstrated upregulated genes CXCR3, CLECSF7 and TLR-9 genes .
There are a number of reasons to explain why our results differ from those previously published. First, we used the more stringent cutoff of greater than or equal to three-fold up- or down-regulation in our analyses to further eliminate potential gene signal noise while Lindstedt et al. used ≥ two-fold . Also, the pDC used in Lindstedt’s study were obtained from children who underwent tonsillectomies  while our pDC came from the peripheral blood of healthy adults. Aging can affect both the phenotype and the function of human monocytes and leukocytes . Additionally, cord blood-derived monocytes and adult monocytes have been demonstrated to have differential gene profiles at rest and when stimulated with LPS . Therefore it is conceivable that the unstimulated pDC from our older adult donors would express different levels of immune-related genes when compared to the same subtypes obtained from children undergoing tonsillectomies.
In summary, we have utilized FACS and MACS to successfully isolate highly purified populations of pDC from healthy donors and present the genetic signatures of these cells. We have identified several upregulated genes in pDC when compared to the CD14+ monocytes with the gene encoding the effector enzyme, Granzyme B, being the most upregulated in our isolated pDC, suggesting an effector function of these cells in the peripheral blood of healthy adults. The genetic profiles from the pDC in our studies differed from those published by Lindstedt et al. This may be due to a combination of setting different cutoff points for considering significant up- and down-regulation of gene expression as well as using cells obtained from older donors. Our results yield further information regarding unstimulated pDCs de novo providing an additional foundation for developing human DC tumor vaccines.
We would like to thank C. Ringelberg for assistance in analyzing the gene chip array data and J. Uhlenhake for technical assistance with the DC subset isolations and RT PCR experiments. Supported by grants from the NIH (RO1 CA095648) (M.E.), Norris Cotton Cancer Center (NCCC Cancer Center Support Grant #5P30CA023108) (M.E.) and the Hitchcock Foundation (M.E. and S.W.).
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.